✦ LIBER ✦

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience

✍ Scribed by Tommaso Caravita; Agostina Siniscalchi; Andrea Tendas; Luca Cupelli; Micaela Ales; Alessio Perrotti; Pasquale Niscola; Paolo de Fabritiis

Book ID: 105989611
Publisher: Springer
Year: 2010
Tongue: English
Weight: 60 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-010-0967-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expanded safety experience with lenalido

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

✍ Christine Chen; Donna E. Reece; David Siegel; Ruben Niesvizky; Ralph V. Boccia; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Efficacy and safety of melphalan, arseni

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study

✍ James R. Berenson; Ralph Boccia; David Siegel; Marek Bozdech; Alberto Bessudo; E 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

Impact of prior therapies on the relativ

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Dan T. Vogl; Edward A. Stadtmauer; Paul G. Richardson; Pieter Sonneveld; Michael 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB